AU Patent

AU2019234574A1 — Inhibitors of tyrosine kinase 2 mediated signaling

Assigned to AbbVie Inc · Expires 2020-09-03 · 6y expired

What this patent protects

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R

USPTO Abstract

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R

Drugs covered by this patent

Patent Metadata

Patent number
AU2019234574A1
Jurisdiction
AU
Classification
—
Expires
2020-09-03
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.